Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Short-term Investments: 2011-2025

Historic Short-term Investments for Arrowhead Pharmaceuticals (ARWR) over the last 14 years, with Sep 2025 value amounting to $692.8 million.

  • Arrowhead Pharmaceuticals' Short-term Investments rose 19.81% to $692.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $692.8 million, marking a year-over-year increase of 19.81%. This contributed to the annual value of $692.8 million for FY2025, which is 19.81% up from last year.
  • Arrowhead Pharmaceuticals' Short-term Investments amounted to $692.8 million in FY2025, which was up 19.81% from $578.3 million recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Short-term Investments registered a high of $692.8 million during FY2025, and its lowest value of $126.7 million during FY2021.
  • Its 3-year average for Short-term Investments is $521.3 million, with a median of $578.3 million in 2024.
  • Data for Arrowhead Pharmaceuticals' Short-term Investments shows a peak YoY surged of 111.79% (in 2022) over the last 5 years.
  • Arrowhead Pharmaceuticals' Short-term Investments (Yearly) stood at $126.7 million in 2021, then spiked by 111.79% to $268.4 million in 2022, then climbed by 9.07% to $292.7 million in 2023, then surged by 97.54% to $578.3 million in 2024, then grew by 19.81% to $692.8 million in 2025.